RxDoctor Payments Data

Amber Demerath, NP

Nurse Practitioner · Neenah, WINPI 1356072417

Payments from drug & device makers

$4,540in general payments, 2019–2025

Across 155 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novartis$441
  • Travere Therapeutics, Inc.$261
  • AstraZeneca$210
  • Otsuka America Pharmaceutical, Inc.$207
  • Ardelyx, Inc.$193
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,46198%
  • Education$792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,540 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,654
Medicare patients
59
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate17$31,093
VelphoroSucroferric Oxyhydroxide13$26,793
Sevelamer Carbonate70$15,706
JardianceEmpagliflozin22$13,724
VeltassaPatiromer Calcium Sorbitex11$10,809
LokelmaSodium Zirconium Cyclosilicate13$6,510
Calcitriol221$4,743
Calcium Acetate27$2,071
Doxazosin Mesylate25$743
Hydralazine Hcl63$640
Potassium Chloride26$529
Losartan Potassium22$345
Furosemide60$328
Amlodipine Besylate38$299
Nifedipine ErNifedipine11$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$104$26,79313 claims
Boehringer IngelheimJardiance$133$13,72422 claims
AstraZenecaLokelma$210$6,51013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Neenah

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →